NARI vs. IMVT

Last updated Jun 4, 2026

NARI (Inari Medical, Inc.) and IMVT (Immunovant, Inc.) are both stocks. Both are in the Healthcare sector — NARI in Medical Devices, IMVT in Biotechnology. At a 0.18 correlation, their price movements are largely independent.

Performance

NARI vs. IMVT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Inari Medical, Inc. (NARI) and Immunovant, Inc. (IMVT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

NARI

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

IMVT

• 1D: 0.74%
• 1M: 11.85%
• YTD: 22.54%
• 6M: 37.16%
• 1Y: 101.75%
• 3Y*: 14.67%
• 5Y*: 25.69%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

NARI vs. IMVT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
NARI Inari Medical, Inc.	0.00%	56.65%	-21.36%	2.14%	-30.36%	4.56%	105.34%
IMVT Immunovant, Inc.	22.54%	2.62%	-41.21%	137.35%	108.33%	-81.55%	130.83%

Correlation

The correlation between NARI and IMVT is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (3Y) Calculated over the trailing 3-year period	0.12
Correlation (5Y) Calculated over the trailing 5-year period	0.20
Correlation (All Time) Calculated using the full available price history since May 26, 2020	0.18

Fundamentals

Total Revenue (TTM) NARI : $574.50M IMVT : $0.00
Gross Profit (TTM) NARI : $494.08M IMVT : -$206.00K
EBITDA (TTM) NARI : -$36.16M IMVT : -$527.21M

Return for Risk

NARI vs. IMVT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMVT

IMVT Risk / Return Rank: 86
IMVT Sharpe Ratio Rank: 83
IMVT Sortino Ratio Rank: 87
IMVT Omega Ratio Rank: 81
IMVT Calmar Ratio Rank: 91
IMVT Martin Ratio Rank: 89

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NARI vs. IMVT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Inari Medical, Inc. (NARI) and Immunovant, Inc. (IMVT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	NARI	IMVT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.64	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.35	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.14	—

Drawdowns

Drawdown Indicators

	NARI	IMVT	Difference
Max Drawdown Largest peak-to-trough decline	—	-93.59%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-20.98%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-69.88%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-70.38%	—
Current Drawdown Current decline from peak	—	-40.90%	—
Average Drawdown Average peak-to-trough decline	—	-54.01%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	9.07%	—

Volatility

Volatility by Period

	NARI	IMVT	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	33.78%	—
Volatility (6M) Calculated over the trailing 6-month period	—	44.71%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	62.24%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	74.80%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	78.28%	—

Dividends

NARI vs. IMVT - Dividend Comparison

Neither NARI nor IMVT has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both NARI and IMVT in my portfolio?

NARI and IMVT have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.